Long-term Treatment Outcomes of Upadacitinib for Crohn's Disease: A Single-center Retrospective Study

Clicks: 3
ID: 315389
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #27 of 38 articles by views in Crohn s & Colitis 360

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Upadacitinib is the sole Janus kinase inhibitor approved for Crohn’s disease in Japan, with its short-term efficacy already known. However, its long-term real-world outcomes remain unclear. This study aimed to evaluate its long-term continuation rates in patients with Crohn’s disease and to identify predictive factors for sustained treatment. Methods This single-center retrospective study included 41 patients with Crohn’s disease treated with upadacitinib between July 2023 and April 2025. Continuation rates at 1 and 2 years defined the primary outcomes. Furthermore, predictive factors for treatment discontinuation, predictive scoring system development, upadacitinib’s effects on perianal draining fistulas, endoscopic outcomes, and adverse events were the secondary outcomes. Results The cumulative continuation rates were 67% and 63% at 1 and 2 years, respectively. In univariate analysis, factors such as age ≥ 40 years, penetrating disease behavior, prior intestinal resection, small-bowel stoma, prior exposure to ≥ 3 biologics, low baseline inflammation (C-reactive protein < 0.34 mg/dL and Simple Endoscopic Score for Crohn’s Disease < 8), week 4 hemoglobin < 11.4 g/dL, week 4 albumin < 4.1 g/dL, and 5-aminosalicylic acid nonuse were associated with upadacitinib discontinuation. A predictive scoring system (0–8 points) demonstrated that patients with scores <3 had significantly better continuation rates than those with scores ≥3 (median: 703 vs. 341 days). Within 24 weeks of upadacitinib use, 2 of 5 patients developed perianal fistula closure. Conclusions In Crohn’s disease, upadacitinib continuation rates can be predicted using baseline patient characteristics and early biomarkers at week 4.
Reference Key
openalex_W7162862708 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Takahiro Ito, Kohei Matsunaga, Yuya Ohno, Muchir Shi, Atsuo Maemoto
Journal Crohn s & Colitis 360
Year 2026
DOI
10.1093/crocol/otag047
URL
https://doi.org/10.1093/crocol/otag047
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.